Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The practicing clinician and regulatory safety concerns.

McAllister RG Jr, Franson T, Kraus CN.

Curr Drug Saf. 2013 Feb;8(1):17-24.

PMID:
23656444
2.

Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States.

Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E.

J Gen Intern Med. 2013 Oct;28(10):1368-75. doi: 10.1007/s11606-013-2411-7. Epub 2013 Apr 5.

3.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
4.

[The origin of informed consent].

Mallardi V.

Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27. Italian.

PMID:
16602332
5.

An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.

Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.

J Ment Health Policy Econ. 2002 Mar;5(1):3-19.

PMID:
12529566
6.

Drugs and trials: lessons from Plato.

Trachtman H.

Clin Ther. 2013 May;35(5):688-91. doi: 10.1016/j.clinthera.2013.03.018. Epub 2013 Apr 13. No abstract available.

7.

Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.

Slevin KA, Ashburn MA.

J Opioid Manag. 2011 Mar-Apr;7(2):109-15.

PMID:
21561034
8.

Methodological approaches to evaluate the impact of FDA drug safety communications.

Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J.

Drug Saf. 2015 Jun;38(6):565-75. doi: 10.1007/s40264-015-0291-y. Erratum in: Drug Saf. 2015 Sep;38(9):845.

PMID:
25968811
9.

Communicating the risks of medicines: time to move forward.

Dal Pan GJ.

Med Care. 2012 Jun;50(6):463-5. doi: 10.1097/MLR.0b013e31825852f0. No abstract available.

PMID:
22581011
10.
11.

Improving communication of drug risks to prevent patient injury: proceedings of a workshop.

Campbell WH, Califf RM.

Pharmacoepidemiol Drug Saf. 2003 Apr-May;12(3):183-94.

PMID:
12733471
12.

The challenge of effectively communicating patient safety information.

Hugman B, Edwards IR.

Expert Opin Drug Saf. 2006 Jul;5(4):495-9.

PMID:
16774488
13.

Childhood vaccine risk/benefit communication in private practice office settings: a national survey.

Davis TC, Fredrickson DD, Arnold CL, Cross JT, Humiston SG, Green KW, Bocchini JA Jr.

Pediatrics. 2001 Feb;107(2):E17.

PMID:
11158491
14.

Allergies: essential patient information for safe practice.

Paparella S.

J Emerg Nurs. 2009 Jun;35(3):239-41. doi: 10.1016/j.jen.2009.01.006. Epub 2009 Feb 27. No abstract available.

PMID:
19446132
15.

Cyberpharmacies and the role of the US Food And Drug Administration.

Henney JE.

J Med Internet Res. 2001 Jan-Mar;3(1):E3.

16.

FDA drug safety communications: a narrative review and clinical considerations for older adults.

Marcum ZA, Vande Griend JP, Linnebur SA.

Am J Geriatr Pharmacother. 2012 Aug;10(4):264-71. doi: 10.1016/j.amjopharm.2012.05.002. Epub 2012 Jun 8. Review.

17.

A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.

Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW.

Value Health. 2010 Aug;13(5):657-66. doi: 10.1111/j.1524-4733.2010.00725.x. Epub 2010 Apr 15. Review.

18.

Need to develop new nonsteroidal anti-inflammatory drug formulations.

McCarberg B, Gibofsky A.

Clin Ther. 2012 Sep;34(9):1954-63. doi: 10.1016/j.clinthera.2012.08.005. Epub 2012 Aug 30. Review.

PMID:
22939163
19.

Physicians' interpretation of "class effects": a need for thoughtful re-evaluation.

Kennedy HL, Rosenson RS.

J Am Coll Cardiol. 2002 Jul 3;40(1):19-26. Review.

20.

The safety assessment process--setting the scene: an FDA perspective.

Schechtman LM.

ILAR J. 2002;43 Suppl:S5-10. Review.

PMID:
12388844

Supplemental Content

Support Center